4.7 Article

Prevalence of BRCA homopolymeric indels in an ION Torrent-based tumour-to-germline testing workflow in high-grade ovarian carcinoma

Related references

Note: Only part of the references are listed.
Article Oncology

Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective

Thomas J. Herzog et al.

Summary: PARP inhibitors have shown clinical activity in patients with BRCA1 and/or BRCA2 mutated breast, ovarian, prostate, and pancreatic cancers. The sensitivity to PARPi is not only limited to tumors with BRCA mutations but also observed in tumors with HRD phenotype. Regulatory agencies have approved companion and complementary diagnostics to facilitate patient selection for PARPi treatment. This review aims to summarize the biological basis, clinical validation, and clinical relevance of diagnostic methods and assays to assess HRD.

EUROPEAN JOURNAL OF CANCER (2023)

Article Oncology

Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing

P. Terraf et al.

Summary: Tumor-only sequencing is suitable for the detection of clinically actionable germline variants, particularly for single-nucleotide variants (SNVs) and small indels. However, for alterations affecting HRD, DDR, and MMR genes, the detection may not be optimal. Clinical genetic testing should be considered for high-risk patients with negative tumor-only sequencing results.

ANNALS OF ONCOLOGY (2022)

Review Oncology

Systematic review of the CUP trials characteristics and perspectives for next-generation studies

Elie Rassy et al.

Summary: The paper summarizes and evaluates therapeutic research for unknown primary cancer (CUP) over the past five years. Based on this evaluation, recommendations for clinical trial designs are made to improve the impact of CUP research on patients.

CANCER TREATMENT REVIEWS (2022)

Article Oncology

Germline sequencing for presumed germline pathogenic variants via tumor-only comprehensive genomic profiling

Tomohiro Kondo et al.

Summary: This study investigated the clinical validity of applying ESMO-PMWG criteria for selecting PGPVs in daily clinical practice. The results suggested that ESMO-PMWG criteria are helpful in selecting PGPVs with a high likelihood of germline origin.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2022)

Article Oncology

Precision medicine-based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience

Bryan H. Louie et al.

Summary: Personalized combination therapy based on molecular characteristics can be more effective for advanced colorectal cancer. The implementation of a Molecular Tumor Board (MTB) led to improved progression-free survival in patients by matching drugs to individual tumor alterations.

MOLECULAR ONCOLOGY (2022)

Article Oncology

Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model

Jacopo Azzollini et al.

Summary: This study evaluates the performance of a tumour-to-germline diagnostic flowchart model in identifying patients with BRCA gene mutations. The results show that this model is more effective in identifying carriers of BRCA gene mutations compared to guideline-based germline testing following genetic counselling.

FRONTIERS IN ONCOLOGY (2022)

Review Oncology

BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside

Stergios Boussios et al.

Summary: DNA damage is a hallmark of cancer. Epithelial ovarian cancer (EOC) and prostate cancer often have defects in DNA damage response (DDR) pathways. PARP inhibitors are a therapeutic strategy for EOC and prostate cancer, particularly in tumors with HR deficiency. Genetic testing plays an increasingly important role in the treatment of ovarian and prostate cancer patients.

CANCERS (2022)

Article Genetics & Heredity

Methylation Analyses Reveal Promoter Hypermethylation as a Rare Cause of Second Hit in Germline BRCA1-Associated Pancreatic Ductal Adenocarcinoma

Binbin Zheng-Lin et al.

Summary: In patients with gBRCA1-PDAC, loss of heterozygosity is the main inactivating mechanism of the wild-type BRCA1 allele in the tumor, and methylation of the BRCA1 promoter is a distinctly uncommon occurrence.

MOLECULAR DIAGNOSIS & THERAPY (2022)

Article Oncology

Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial

Darren R. Hodgson et al.

Summary: The study demonstrates high concordance between tumor and germline BRCA testing in ovarian cancer patients, supporting wider implementation of tumor BRCA testing in the clinical setting. Near 100% rates of bi-allelic loss of BRCA in platinum-sensitive relapsed ovarian tumors suggest routine testing for BRCA zygosity may not be necessary in this population.

GYNECOLOGIC ONCOLOGY (2021)

Article Oncology

Germline Testing Data Validate Inferences of Mutational Status for Variants Detected From Tumor-Only Sequencing

Nahed Jalloul et al.

Summary: Analyzing tumor-only sequencing data can help determine the germline or somatic status of variants, with high accuracy in inferring the types of variants. Variants in known hereditary tumor suppressors are more likely to have loss of heterozygosity in tumor specimens.

JCO PRECISION ONCOLOGY (2021)

Article Oncology

Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition

Janet R. Vos et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)

Article Medicine, General & Internal

Yield and Utility of Germline Testing Following Tumor Sequencing in Patients With Cancer

Stephen E. Lincoln et al.

JAMA NETWORK OPEN (2020)

Article Biochemical Research Methods

Strategies for identification of somatic variants using the Ion Torrent deep targeted sequencing platform

Aditya Deshpande et al.

BMC BIOINFORMATICS (2018)

Article Multidisciplinary Sciences

Comparison of error correction algorithms for Ion Torrent PGM data: application to hepatitis B virus

Liting Song et al.

SCIENTIFIC REPORTS (2017)

Review Biochemistry & Molecular Biology

Implementing Genome-Driven Oncology

David M. Hyman et al.

Article Biochemical Research Methods

Denoising DNA deep sequencing data-high-throughput sequencing errors and their correction

David Laehnemann et al.

BRIEFINGS IN BIOINFORMATICS (2016)

Article Biotechnology & Applied Microbiology

Improving alignment accuracy on homopolymer regions for semiconductor-based sequencing technologies

Weixing Feng et al.

BMC GENOMICS (2016)

Article Oncology

Inherited Mutations in Women With Ovarian Carcinoma

Barbara M. Norquist et al.

JAMA ONCOLOGY (2016)

Article Biochemistry & Molecular Biology

Streamlined ion torrent PGM-based diagnostics: BRCA1 and BRCA2 genes as a model

Julien Tarabeux et al.

EUROPEAN JOURNAL OF HUMAN GENETICS (2014)

Article Biotechnology & Applied Microbiology

Genetic Testing in Hereditary Breast and Ovarian Cancer Using Massive Parallel Sequencing

Anna Ruiz et al.

BIOMED RESEARCH INTERNATIONAL (2014)

Article Biochemistry & Molecular Biology

Next-generation sequencing meets genetic diagnostics: development of a comprehensive workflow for the analysis of BRCA1 and BRCA2 genes

Lidia Feliubadalo et al.

EUROPEAN JOURNAL OF HUMAN GENETICS (2013)

Review Oncology

Genomics-Driven Oncology: Framework for an Emerging Paradigm

Levi A. Garraway

JOURNAL OF CLINICAL ONCOLOGY (2013)

Article Biotechnology & Applied Microbiology

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

Garrett M. Frampton et al.

NATURE BIOTECHNOLOGY (2013)

Article Biotechnology & Applied Microbiology

Performance comparison of benchtop high-throughput sequencing platforms

Nicholas J. Loman et al.

NATURE BIOTECHNOLOGY (2012)

Article Multidisciplinary Sciences

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer

SA Tomlins et al.

SCIENCE (2005)